The addition of everolimus, an mTOR inhibitor, to an aromatase inhibitor in patients with hormone receptor positive metastatic BC and to trastuzumab and vinorelbine in patients with HER2-positive BC led to im-proved survival outcomes in randomized placebo-controlled phase III trials [176,177]. Here, NR4A1 is linked to breast cancer.